Piwi‑piRNA Reactivation in Cochlear Somatic Cells Mitigates Transposon‑Driven Genomic Instability and Age‑Related Hearing Loss

Hypothesis: Reactivating the germline‑specific Piwi‑piRNA transposon silencing pathway in post‑mitotic spiral ganglion neurons (SGNs) and stria vascularis marginal cells will suppress age‑associated LINE‑1 activity, reduce DNA damage, and preserve cochlear function.

Rationale Germ cells maintain genomic integrity across generations not by superior repair but by ruthless culling of defective lineages and constitutive suppression of transposable elements (TEs) via telomerase, epigenetic resetting, enhanced proteostasis, mitochondrial quality control, and the Piwi‑piRNA/Polycomb system [2]. Somatic tissues, including the cochlea, largely lack this defense, allowing TE mobilization to drive age‑related genomic disintegration [3]. In the aging cochlea, SGNs undergo intrinsic mitochondrial apoptosis [4] and strial marginal cells suffer oxidative mitochondrial dysfunction [4], yet no study has examined whether these post‑mitotic cells lack or lose germline‑type TE silencing. The disposable soma theory predicts that somatic cells forego costly TE suppression to allocate resources to reproduction [5], creating a testable vulnerability: if Piwi‑piRNA activity declines with age, TEs become active, exacerbating DNA damage and accelerating SGN and strial cell loss.

Mechanistic Model Age‑related oxidative stress in the cochlea downregulates PiwiL2 expression and associated piRNA biogenesis. Loss of Piwi‑mediated cleavage permits LINE‑1 retrotransposition, generating new insertions and double‑strand breaks. Accumulated DNA damage activates the cGAS‑STING pathway, provoking a chronic inflammatory milieu that further impairs mitochondrial function and elevates reactive oxygen species. This vicious cycle drives SGN apoptosis via Bax up‑regulation/Bcl‑2 down‑regulation [4] and compromises strial ion transport, manifesting as elevated auditory brainstem response (ABR) thresholds and reduced endocochlear potential.

Testable Predictions

1. PiwiL2 protein and mature piRNA levels decline significantly in mouse SGNs and strial cells between 3 and 18 months of age.
2. Concomitant increases in LINE‑1 ORF1p expression and γH2AX foci will be detectable in the same tissues.
3. Cochlear‑specific overexpression of PiwiL2 (via AAV) in aged mice will restore LINE‑1 silencing, reduce γH2AX signaling, lower mitochondrial ROS (MitoSOX), and preserve SGN and strial cell counts.
4. Functional rescue will be evidenced by improved ABR thresholds (≤10 dB shift relative to young controls) and preserved distortion product otoacoustic emissions (DPOAEs).
5. Pharmacological activation of the Piwi pathway (e.g., using N6‑methyladenosine‑enhanced small RNAs) will phenocopy the genetic rescue, confirming that the effect is mediated through TE silencing rather than off‑target AAV effects.

Experimental Approach

• Generate AAV‑PHP.eB vectors carrying PiwiL2 under the prestin (for outer hair cells/strial marginal cells) or Vglut1 (for SGNs) promoter; include AAV‑GFP as control.
• Inject vectors into the cochlea of 12‑month‑old C57BL/6J mice; allow 4 weeks for expression.
• Harvest tissues at 18 months for:
  • RT‑qPCR and small‑RNA sequencing to quantify PiwiL2 and piRNA populations.
  • Immunofluorescence for LINE‑1 ORF1p and γH2AX; confocal microscopy to count foci per nucleus.
  • MitoSOX staining to assess mitochondrial superoxide.
  • SGN survival (NeuN⁺/TUNEL⁻) and strial marginal cell density (Kcnq1⁺/Na⁺/K⁺‑ATPase⁺).
  • Auditory function: ABR thresholds at 4, 8, 16, 32 kHz and DPOAE amplitudes.
• Parallel cohort treated with synthetic piRNA mimics delivered via liposomes to test pharmacological rescue.

Potential Outcomes and Implications If PiwiL2 re‑expression attenuates LINE‑1 activity, reduces DNA damage, and preserves hearing, the hypothesis will be supported, revealing a conserved germline‑specific anti‑aging mechanism that can be harnessed in somatic tissues. Conversely, if TE silencing does not correlate with functional outcomes, alternative drivers of cochlear aging (e.g., pure metabolic failure or immune‑mediated damage) would be implicated, redirecting therapeutic focus. Either result clarifies the role of transposon control in sensory neuron longevity and informs strategies to extend the functional lifespan of the auditory system.